Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 4/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25802327 | 1.00 | KDR (0.42) | KDRFLT1CYP17A1RETMAPK14 | |
| SCHEMBL25793135 | 0.93 | KDR (0.43) | KDRFLT1CYP17A1RETMAPK14 | |
| SCHEMBL30486123 | 0.92 | KDR (0.35) | KDRFLT1RETPDGFRABRAF | |
| SCHEMBL25802350 | 0.92 | KDR (0.35) | KDRFLT1RETPDGFRABRAF | |
| SCHEMBL25241282 | 0.91 | KDR (0.40) | KDRFLT1RETMAPK14KIT | |
| SCHEMBL29959168 | 0.87 | KDR (0.43) | KDRFLT1CYP17A1RETMAPK14 | |
| SCHEMBL25793116 | 0.87 | KDR (0.43) | KDRFLT1CYP17A1RETMAPK14 | |
| SCHEMBL25793134 | 0.86 | KDR (0.45) | KDRFLT1CYP17A1KITPDGFRA | |
| SCHEMBL25286541 | 0.84 | BRAF (0.39) | KDRFLT1RETKITPDGFRA | |
| SCHEMBL25793117 | 0.84 | KDR (0.44) | KDRFLT1CYP17A1RETMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177382-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2022226182-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDR 4751/4885FLT1 4178/4885CYP17A1 3979/4885 |
| US-20250177382-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | KDR 4717/4885FLT1 4274/4885CYP17A1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.